{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:03:34Z","timestamp":1793286214703,"version":"4.5.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of various malignancies, particularly melanoma. However, immune-related adverse events (irAEs) pose significant challenges, particularly in cases of severe toxicity syndromes. One such life-threatening irAE is the myocarditis, myositis, and myasthenia gravis (MMM) overlap syndrome, which occurs in less than 1% of patients but has in-hospital mortality rates ranging from 40 to 60%. Due to its rarity and complexity, early recognition and a multidisciplinary approach are critical to improving outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We present a single-institution case series of four patients diagnosed with MMM overlap syndrome following ICI therapy. Clinical presentation, laboratory findings, imaging, and electrophysiological tests were analyzed to confirm the diagnosis. Therapeutic interventions-including corticosteroids, intravenous immunoglobulins (IVIG), plasma exchange (PLEX), tocilizumab, and rituximab- were evaluated in terms of efficacy and clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The onset of MMM syndrome varied from 2 to 4 weeks after initiating ICI therapy. Patients presented with rapidly progressive symptoms, including ptosis, bulbar dysfunction, respiratory distress, myopathy, and cardiac conduction abnormalities. Immunosuppressive therapy with high-dose corticosteroids was initiated in all cases. Additional immunomodulatory treatments (IVIG, tocilizumab, PLEX, and rituximab) were administered based on clinical deterioration and autoimmune profile. Two patients achieved complete recovery, one remains on maintenance immunosuppression, and one died due to respiratory failure despite aggressive treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MMM overlap syndrome is a severe and often fatal irAE associated with ICI therapy. Early identification, aggressive immunosuppressive treatment, and individualized therapeutic strategies are essential to optimize patient outcomes. Further research is needed to refine diagnostic criteria, identify predictive biomarkers, and establish standardized treatment protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1597259","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:26:17Z","timestamp":1746667577000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":44,"title":["Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Alberto","family":"S\u00e1nchez-Camacho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Torres-Zurita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gallego-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Hern\u00e1ndez-Pacheco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Silva-Romeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda del Carmen","family":"\u00c1lamo de la Gala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Peral-Guti\u00e9rrez de Ceballos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"de la Cruz-Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jamadermatol.2023.3003","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment","volume":"159","author":"Du","year":"2023","journal-title":"JAMA Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2017","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3145","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III\/IV melanoma: 5-year efficacy and biomarker results from CheckMate 238","volume":"29","author":"Larkin","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2118309","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1155\/2024\/5399073","article-title":"Immunotherapy-induced overlap syndrome: myositis, myasthenia gravis, and myocarditis\u2014a case series","volume":"2024","author":"Aggarwal","year":"2024","journal-title":"Case Rep Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14161794","article-title":"Myocarditis, myositis, and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors: a systematic review","volume":"14","author":"Lipe","year":"2024","journal-title":"Diagnostics"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13931","article-title":"Immune checkpoint inhibitor\u2013induced myocarditis with myositis\/myasthenia gravis overlap syndrome: a systematic review of cases","volume":"26","author":"Pathak","year":"2021","journal-title":"Oncologist"},{"key":"B19","article-title":"Common terminology criteria for adverse events (CTCAE) version 5","year":"2017"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k4226","article-title":"Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis","volume":"363","author":"Xu","year":"2018","journal-title":"BMJ"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx388","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Prime"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.4047","article-title":"Predictors of immunotherapy-induced immune-related adverse events","volume":"25","author":"Kartolo","year":"2018","journal-title":"Curr Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1288844","article-title":"HLA inherence as a potential parameter in checkpoint inhibitor-associated autoimmune adverse event assessment","volume":"10","author":"Gandarillas","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12967-018-1466-4","article-title":"Sex and Interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade","volume":"16","author":"Valpione","year":"2018","journal-title":"J Transl Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051629","article-title":"Predictive biomarkers for checkpoint inhibitor immune-related adverse events","volume":"15","author":"Les","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.858628","article-title":"Association between clinical factors and result of immune checkpoint inhibitor related myasthenia gravis: A single center experience and systematic review","volume":"13","author":"Shi","year":"2022","journal-title":"Front Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241310919","article-title":"Pembrolizumab-induced fatal myasthenia, myocarditis, and myositis in a patient with metastatic melanoma: autopsy, histological, and immunohistochemical findings\u2014A case report and literature review","volume":"24","author":"Giovannini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0805-8","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200177","article-title":"Immune checkpoint inhibition\u2013related myasthenia-myositis-myocarditis responsive to complement blockade","volume":"11","author":"Nelke","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.carpath.2020.107211","article-title":"Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: pathway toward precision-based therapy","volume":"47","author":"Balanescu","year":"2020","journal-title":"Cardiovasc Pathol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12956","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.11482\/KMJ-E43(2)59","article-title":"Successful reinstitution of nivolumab in combination with corticosteroids for metastatic Malignant melanoma with myasthenia gravis as an immune-related adverse event","volume":"43","author":"Tanaka","year":"2017","journal-title":"Kawasaki Med J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009262","article-title":"Coexisting myasthenia gravis, myositis, and polyneuropathy induced by ipilimumab and nivolumab in a patient with non-small cell lung cancer: a case report and literature review","volume":"96","author":"Chen","year":"2017","journal-title":"Med (Baltimore)"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.11.022","article-title":"Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody","volume":"106","author":"Shirai","year":"2019","journal-title":"Eur J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s00520-023-07987-x","article-title":"Immune-checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: a case series","volume":"31","author":"Weaver","year":"2023","journal-title":"Supp Care Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1199031","article-title":"Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy\u2014review of the literature and future outlook","volume":"8","author":"Mohn","year":"2019","journal-title":"J Clin Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barre Syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"McNeill","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2024.100111","article-title":"Cardiovascular toxicities in cancer patients treated with immune checkpoint inhibitors: multicenter study using natural language processing on Belgian hospital data","volume":"7","author":"Delombaerde","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalized myasthenia gravis (ADAPT)","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597259\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T01:26:19Z","timestamp":1746667579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1597259\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":52,"alternative-id":["10.3389\/fimmu.2025.1597259"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1597259","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"article-number":"1597259"}}